These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
868 related articles for article (PubMed ID: 26998644)
1. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin. Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644 [TBL] [Abstract][Full Text] [Related]
2. PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. Du JB; Song YF; Ye WL; Cheng Y; Cui H; Liu DZ; Liu M; Zhang BL; Zhou SY Anticancer Drugs; 2014 Aug; 25(7):751-66. PubMed ID: 24590167 [TBL] [Abstract][Full Text] [Related]
3. Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy. Bi D; Zhao L; Yu R; Li H; Guo Y; Wang X; Han M Drug Deliv; 2018 Nov; 25(1):564-575. PubMed ID: 29457518 [TBL] [Abstract][Full Text] [Related]
4. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin. Song YF; Liu DZ; Cheng Y; Teng ZH; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY Mol Pharm; 2018 Mar; 15(3):1296-1308. PubMed ID: 29432025 [TBL] [Abstract][Full Text] [Related]
5. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery. Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742 [TBL] [Abstract][Full Text] [Related]
6. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles. Tonbul H; Şahin A; Öztürk SC; Ultav G; Tavukçuoğlu E; Akbaş S; Aktaş Y; Esendağlı G; Çapan Y J Drug Target; 2024 Nov; 32(9):1101-1110. PubMed ID: 38946465 [TBL] [Abstract][Full Text] [Related]
7. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091 [TBL] [Abstract][Full Text] [Related]
8. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. He Y; Su Z; Xue L; Xu H; Zhang C J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977 [TBL] [Abstract][Full Text] [Related]
9. Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics. Shen X; Li T; Chen Z; Geng Y; Xie X; Li S; Yang H; Wu C; Liu Y Int J Nanomedicine; 2017; 12():4299-4322. PubMed ID: 28652734 [TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784 [TBL] [Abstract][Full Text] [Related]
11. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation. Wang J; Li L; Wu L; Sun B; Du Y; Sun J; Wang Y; Fu Q; Zhang P; He Z Eur J Pharm Sci; 2017 Mar; 99():185-192. PubMed ID: 27989702 [TBL] [Abstract][Full Text] [Related]
12. Folate-containing reduction-sensitive lipid-polymer hybrid nanoparticles for targeted delivery of doxorubicin. Wu B; Yu P; Cui C; Wu M; Zhang Y; Liu L; Wang CX; Zhuo RX; Huang SW Biomater Sci; 2015 Apr; 3(4):655-64. PubMed ID: 26222425 [TBL] [Abstract][Full Text] [Related]
13. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. Ye WL; Du JB; Zhang BL; Na R; Song YF; Mei QB; Zhao MG; Zhou SY PLoS One; 2014; 9(5):e97358. PubMed ID: 24828815 [TBL] [Abstract][Full Text] [Related]
14. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects. Gao F; Li L; Liu T; Hao N; Liu H; Tan L; Li H; Huang X; Peng B; Yan C; Yang L; Wu X; Chen D; Tang F Nanoscale; 2012 Jun; 4(11):3365-72. PubMed ID: 22538830 [TBL] [Abstract][Full Text] [Related]
15. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles. Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911 [TBL] [Abstract][Full Text] [Related]
16. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment. Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140 [TBL] [Abstract][Full Text] [Related]
17. Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization and in vivo antitumor activity. Zhang C; Zhang Z; Zhao L Drug Deliv; 2016 Jun; 23(5):1830-7. PubMed ID: 26652055 [TBL] [Abstract][Full Text] [Related]
18. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy. Wu G; Wang Z; Bian X; Du X; Wei C Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652 [TBL] [Abstract][Full Text] [Related]
19. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy Men W; Zhu P; Dong S; Liu W; Zhou K; Bai Y; Liu X; Gong S; Zhang S Drug Deliv; 2020 Dec; 27(1):180-190. PubMed ID: 31924103 [TBL] [Abstract][Full Text] [Related]
20. Lipid-Polymer Nanoparticles for Folate-Receptor Targeting Delivery of Doxorubicin. Zheng M; Gong P; Zheng C; Zhao P; Luo Z; Ma Y; Cai L J Nanosci Nanotechnol; 2015 Jul; 15(7):4792-8. PubMed ID: 26373039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]